SBI is enlisting non-exclusive subscriptions for its novel and proprietary structural bioinformatics database, the SBdBase^TM, with customers drawn from the pharmaceutical industry on an international basis. In addition, a number of target-based corporate partnerships are in place that have already successfully led to the discovery of commercially interesting, highly active small molecules now in development.